Weight Loss the Easy Ways
Andrea Albright Featured on Health and Fitness Jan. 2015
will Personally Coach You How to Get There The Easy Way
If You Are Looking For a SoulMate
Celebrity Patti Stanger Will Coach You To Get Him/Her
and Keep Him/Her for Good,The Simple Way
By Kyle J. Norton Health article writer and researcher; Over 10.000
articles and research papers have been written and published on line,
including world wide health, ezine articles, article base, healthblogs,
selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by
Disilgold.com Named 50 of the best health Tweeters Canada - Huffington
Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as
international journal Pharma and Bio science, ISSN 0975-6299.
Polycystic Ovarian Syndrome
Polycystic Ovarian Syndrome
is defined as endocrinologic diseases among reproductive-age women caused by undeveloped follicles
clumping on the ovaries that interferes with the function of the normal
ovaries associated
with a high risk for metabolic disorder(1) as resulting of enlarged
ovaries(2), leading to hormone imbalance(excessive androgen and anti-müllerian hormone (AMH) )(1)(3)(4)(5), induced Hirsutism(6)(7), reproductive disorder(10(12)), risks of type 2 diabetes(9)(10)(11), metabolic syndrome(10)(12) and early cardiovasular disease(8)(13), acne(10)(14), endometrial cance(18)(19),weight
gain and obesity(15)(16)(17). The syndrome effects over 5% of women population or 1
in 20 women.
Unfortunately, according to studies, women with PCOs after the reproductive age, are associated to continuously increase risk of type II diabetes, with no increasing altered glucose tolerance(20), CVD and hypertension(21).
The Diagnosis
If you have experienced some of above symptoms, it is for your benefit
to visit your doctor or gynecologist immediately. PCOs is easy to identify through your
1. Medical
history, including question of your symptoms, such as menstrual
irregularity, weight change, skin and sleep patterns, as well as all
symptoms may contribute to the susceptible PCOs.
a. History of pregnancy including difficulty to conceive, miscarriage, poor neonatal and maternal pregnancy outcomes(46)(47) ...
b. Medication may influence the development of PCOs
2. Physical exam
The
aim of the physicam exam is to check for PCOs symptoms, such as
pelvic exam for enlarge and abnormal ovaries, male pattern hair growth,
acne, weight gain, body mass index (BMI)(48)(49) etc., and risk of
diseases caused by PCOs, such as hypertension, thyroid
abnormality(50)(51).
(Please check citations in the topics of symptoms and risk factors)
3. Pelvic ultrasound
The
aim of the test is to check for enlarge ovaries(2) and cysts(52).
Unfortunately, many women with PCOs do not show these abnormalities.
4. Blood test
The blood test includes testing of
a.
Dehydroepiandrosterone(DHEA), is a test for excess adrenal precursor androgen (APA) production(53)(54) found in approximately 20-30% of women with
PCOS(53).
b Abnormal testosterone(55) levels may interference with the follicle incubation medium(55)(56).
c. Sex hormone-binding globulin (SHBG)(57) is a surrogate marker of insulin resistance
Lower levels of SHBG are found in women with PCOs(58)
d. Follicle-stimulating hormone (FSH)/LH ratio(LH(58) and FSH ratio(58)(59)). Dr. Li Y and the research team at Second Affiliated Hospital of Sun Yat-sen University, said "
PCOS patients with higher
LH/
FSH ratio are primarily caused by hypothalamic-pituitary dysfunction, while the
PCOS patients with normal
LH/
FSH ratio are mainly caused by metabolic disorders"(60).
e. Thyroid-stimulating hormone (TSH)
The aim of the test is to check for levels of TSH (> or =2.5 mIU/l) as the hormone has shown to significantly alter endocrine and metabolic changes(64)
Thyroid
dysfunctionis found to be associated to independent risks of ovarian
failure and pregnancy related complications in women with Polycystic
ovarian syndrome (
PCOS)(61). It is said that both
PCOS
patients combined with SCH have higher risk of cardiovascular risk
factors(62)and subclinical hypothyroidism (SCH) is more common in women
with PCOs(63).
f. IGTT level (fasting insulin)(65)(66)
and several other androgens(67)(68) are used to evaluate adrenal function. If
there are abnormal secretion of certain hormones, you may be at a high
risk of having PCOs.
Low birth weight may contribute the causation of hyperandrogenism and
insulin resistance in adolescents with
PCOS, according to the joint study in Italy(64).
Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months
References
(1) Adiposity and metabolic dysfunction in
polycystic ovary syndrome by Sam S.(
PubMed)
(2) A "kiss" before conception: triggering ovulation with kisspeptin-54 may improve IVF by Young SL.(
PubMed)
(3.)
Androgen hyperfunction and
excessive heterosexual hair growth in women, with special attention to the
polycystic ovarian syndrome by Lunde O
1.(
PubMed)
(4) Expression of anti-Müllerian hormone in letrozole rat model of
polycystic ovary syndrome by Du DF
1, Li XL, Fang F, Du MR.(
PubMed)
(5) [Serum levels of anti-muller hormone in women with
polycystic ovary syndrome and healthy women of reproductive age].[Article in Bulgarian] by Parahuleva N, Pehlivanov B, Orbecova M, Deneva T, Uchikova E.(
PubMed)
(6) [Current opinions on the etiology and pathophysiology of hirsutism].[Article in Polish] by Krysiak R
1, Kedzia A, Okopień B.(
PubMed)
(7) The clinical evaluation of hirsutism by Somani N
1, Harrison S, Bergfeld WF.(
PubMed)
(8)
Polycystic ovary syndrome and insulin: our understanding in the past, present and future by Mayer SB
1, Evans WS, Nestler JE.(
PubMed)
(9) Association of mean platelet volume with androgens and insulin resistance in nonobese patients with
polycystic ovary syndrome by Dogan BA
1, Arduc A
2, Tuna MM
1, Karakılıc E
1, Dagdelen I
1, Tutuncu Y
1, Berker D
1, Guler S
1.(
PubMed)
(10) Approach to the patient: contraception in women with
polycystic ovary syndrome by Yildiz BO
1.(
PubMed)
(11)
Polycystic ovarian syndrome (PCOS): a significant contributor to the overall burden of
type 2 diabetes in women by Talbott EO
1, Zborowski JV, Rager JR, Kip KE, Xu X, Orchard TJ.(
PubMed)
(12) Prevalence of vitamin D deficiency in Slovak women with
polycystic ovary syndrome and its relation to
metabolic and reproductive abnormalities by Figurová J
1, Dravecká I, Javorský M, Petríková J, Lazúrová I.(
PubMed)
(13) Role of Insulin Sensitizers on
Cardiovascular Risk Factors in
Polycystic Ovarian Syndrome: A Meta-Analysis by Thethi TK
1, Katalenich B
2, Nagireddy P
3, Chabbra P
4, Kuhadiya N
5, Fonseca V
1.(
PubMed)
(14)
Acne in hirsute women by Lumezi BG
1, Pupovci HL
1, Berisha VL
1, Goçi AU
2, Gerqari A
3.(
PubMed)
(15) Obesity and
polycystic ovary syndrome by Naderpoor N
1, Shorakae S, Joham A, Boyle J, De Courten B, Teede HJ.(
PubMed)
(16)
Polycystic ovary syndrome:
a complex condition with psychological, reproductive and metabolic
manifestations that impacts on health across the lifespan by Teede H
1, Deeks A, Moran L.(
PubMed)
(17) Metabolic Evidence of Diminished Lipid Oxidation in Women With
Polycystic Ovary Syndrome. by Whigham LD
1, Butz DE
2, Dashti H
3, Tonelli M
3, Johnson LK
1, Cook ME
2, Porter WP
4, Eghbalnia HR
5, Markley JL
6, Lindheim SR
7, Schoeller DA
8, Abbott DH
9, Assadi-Porter FM
10.(
PubMed)
(18) Risk of endometrial,
ovarian and breast cancer in women with
polycystic ovary syndrome: a systematic review and meta-analysis by Barry JA
1, Azizia MM
1, Hardiman PJ
2.(
PubMed)
(19) Risk of
cancer among women with
polycystic ovary syndrome: a Danish cohort study by Gottschau M
1, Kjaer SK
2, Jensen A
1, Munk C
1, Mellemkjaer L
3.(
PubMed)
(20)
Polycystic ovary syndrome: metabolic consequences and long-term management by Carmina E
1.(
PubMed)
(21) Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a
polycystic ovary syndrome phenotype by Armeni E
1,
Stamatelopoulos K, Rizos D, Georgiopoulos G, Kazani M, Kazani A,
Kolyviras A, Stellos K, Panoulis K, Alexandrou A, Creatsa M, Papamichael
C, Lambrinoudaki I.(
PubMed)
(46) Female Obesity and Infertility by Talmor A
1, Dunphy B
2.(
PubMed)
(47) [Reproductive problems in women with
PCOS,
the impact of PAL-1 CARRIERS OF 4G PAI -1 polymorphism and
BMI].[Article in Bulgarian] by Komsa-Penkova R, Golemanov G, Georgieva
G, Slavov N, Popovski K, Ivanov P, Kovacheva K, Atanasova M, Blajev A.(
PubMed)
(48) Endothelial function in young women with polycystic ovary syndrome (
PCOS): Implications of
body mass index (
BMI) and insulin resistance by El-Kannishy G
1, Kamal S
2, Mousa A
2, Saleh O
2, Badrawy AE
2, Farahaty RE
2, Shokeir T
2.(
PubMed)
(49)
Body Mass Index
and Gonadotropin Hormones (LH & FSH) Associate With Clinical
Symptoms Among Women With Polycystic Ovary Syndrome by Esmaeilzadeh S,
Andarieh MG
1, Ghadimi R, Delavar MA.(
PubMed)
(50)
Thyroid
disorders in polycystic ovarian syndrome subjects: A tertiary hospital
based cross-sectional study from Eastern India by Sinha U
1, Sinharay K, Saha S, Longkumer TA, Baul SN, Pal SK.(
PubMed)
(51) The evaluation and management of hirsutism by Azziz R
1.(
PubMed)
(52)
Pcos.[No authors listed](
PubMed)
(53) DHEA,
DHEAS and
PCOS by Goodarzi MO
1, Carmina E2, Azziz R3.(
PubMed)
(54) Adrenal androgen excess and body mass index in polycystic ovary syndrome by Moran C
1, Arriaga M, Arechavaleta-Velasco F, Moran S.(
PubMed)
(55) Superactive human leptin antagonist reverses leptin-induced excessive progesterone and
testosterone secretion in porcine ovarian follicles by blocking leptin receptors by Gregoraszczuk EL
1, Rak A.(PubMed)
(56) Reproduction in hens: is
testosterone necessary for the ovulatory process? by Rangel PL
1, Gutierrez CG
2.(
PubMed)
(57) The value of
sex hormone binding globulin (
SHBG) in predicting treatment response in polycystic ovary syndrome (
PCOS) by Wassell J
1, Michail M, Soliman N, Wardle PG.(
PubMed)
(58) Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance by Nawrocka J
1, Starczewski A.(
PubMed)
(59) Serum luteinizing
hormone level and luteinizing
hormone/
follicle-stimulating hormone ratio but not serum anti-Müllerian
hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome by Chun S
1.(
PubMed)
(60) [Effect of luteinizing
hormone vs follicular
stimulating hormone ratio on anti-Müllerian
hormone secretion and folliculogenesis in patients with polycystic ovarian syndrome].[Article in Chinese] by Li Y
1, Wei LN, Xiong YL, Liang XY.(
PubMed)
(61)
Thyroid
disorders in polycystic ovarian syndrome subjects: A tertiary hospital
based cross-sectional study from Eastern India by Sinha U
1, Sinharay K, Saha S, Longkumer TA, Baul SN, Pal SK.(
PubMed)
(62)
Studies of cardiovascular risk factors in polycystic ovary syndrome
patients combined with subclinical hypothyroidism by Pei YJ
1, Wang AM, Zhao Y, Yan L, Li M, White RE, Han GC.(
PubMed)
(63) Polycystic ovary syndrome and chronic autoimmune thyroiditis by Novais Jde S
1, Benetti-Pinto CL, Garmes HM, Jales RM, Juliato CR.(
PubMed)
(64) Association of
thyroid-stimulating hormone with insulin resistance and androgen parameters in women with
PCOS by Dittrich R
1, Kajaia N, Cupisti S, Hoffmann I, Beckmann MW, Mueller A.(
PubMed)
(65) [Association between
levels of serum leptin and
insulin resistance in patients with polycystic ovary syndrome].[Article in Chinese]by Cheng X
1, Guo J
2, Xie J
3.
(PubMed)
(66) [Clinical study on treating
insulin resistance and promoting ovulation in polycystic ovary syndrome].[Article in Chinese]by Liu ZA
1, Xue YM, Chen LX, Cai Q, Chen H, Zhang J, Cui QH, Ge J, Yuan T.(
PubMed)
(67) Randomized clinical trial evaluating metformin versus oral
contraceptive pills in the treatment of adolescents with polycystic
ovarian syndrome by Al-Zubeidi H, Klein KO.(
PubMed)
(68) Randomized controlled trial evaluating response to metformin versus
standard therapy in the treatment of adolescents with polycystic ovary
syndrome by Allen HF
1, Mazzoni C, Heptulla RA, Murray MA, Miller N, Koenigs L, Reiter EO.(
PubMed)
